Indication assessment · §3
Peripheral arterial disease with intermittent claudication — trial records
Trial records in the Institute's register bearing on peripheral arterial disease with intermittent claudication.
§3Trials in this indication
4 trial records in the Institute's register bear on this indication, of which 1 is a published trial.
Table 2. Trial records bearing on peripheral arterial disease with intermittent claudication.
| Record | Compound | Phase | Design | Randomised | Year |
|---|---|---|---|---|---|
| STRIDE | Semaglutide | Phase 3 | Randomised, double-blind, placebo-controlled | 792 | 2025 |
| STRIDE-QOLprogramme record | Semaglutide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2025 |
| STRIDE-REGIONAL-CNprogramme record | Semaglutide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2025 |
| STRIDE-REGIONAL-JPprogramme record | Semaglutide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2025 |
| This facet in the trial register. | |||||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-IN-16/3 · https://compoundevidence.com/indications/pad/trials/ · retrieved 30 July 2026